Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer.
- Author:
D Nathan KIM
1
;
Taek Keun NAM
;
Kevin S CHOE
;
Hak CHOY
Author Information
1. Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA. hak.choy@utsouthwestern.edu
- Publication Type:Review ; Clinical Trial
- Keywords:
Lung neoplasms;
Individualized medicine;
Tyrosine kinase inhibitor;
Epidermal growth factor receptor;
Combined modality therapy
- MeSH:
Carcinoma, Non-Small-Cell Lung;
Combined Modality Therapy;
Humans;
Precision Medicine;
Lung Neoplasms;
Receptor, Epidermal Growth Factor
- From:Cancer Research and Treatment
2012;44(2):74-84
- CountryRepublic of Korea
- Language:English
-
Abstract:
Locally advanced non-small cell lung cancer (NSCLC) is a heterogeneous disease, and we have embarked on an era where patients will benefit from individualized therapeutic strategies based on identifiable molecular characteristics of the tumor. The landmark studies demonstrating the importance of molecular characterization of tumors for NSCLC patients, the promising molecular pathways, and the potential molecular targets/agents for treatment of this disease will be reviewed. Understanding these issues will aid in the development of rationally designed clinical trials, so as to determine best means of appropriately incorporating these molecular strategies, to the current standard of radiation and chemotherapy regimens, for the treatment of locally advanced NSCLC.
